The human papillomavirus vaccine: Current perspective and future role in prevention and treatment of anal intraepithelialneoplasia and anal cancer

Felix A. Mensah, Mudresh R. Mehta, James S. Lewis, Albert Lockhart

Research output: Contribution to journalArticle

5 Scopus citations


The incidences of human papillomavirus (HPV)-related anal cancer and its precursor lesion, anal intraepithelial neoplasia, are rising in the U.S. and globally. Five-year survival rates with current modalities of treatment for anal cancer are generally favorable for localized and regional disease. For metastatic disease, the relative survival rate is poor. Major contributing factors for the increase in anal cancer incidence include increasing receptive anal intercourse (hetero- and homosexual), increasing HPV infections, and longer life expectancy of treated people who are seropositive for human immunodeficiency virus. Because treatment outcomes with systemic therapy in patientswith advanced disease are so poor, preventionmay be the best approach for reducing disease burden.The association ofamajorcausativeagentwithanalcancerprovidesanexcellent opportunity for prevention and treatment. The advent of the HPV vaccine for anal cancer prevention and treatment is a significant milestone and has the potential to greatly impact these cancers. The data regarding potential use of the HPV vaccine in anal cancer prevention and treatment are reviewed.

Original languageEnglish (US)
Pages (from-to)453-460
Number of pages8
Issue number4
StatePublished - Apr 1 2016
Externally publishedYes



  • Anal intraepithelial neoplasia
  • Anus neoplasm
  • Carcinoma
  • Papillomavirus infection
  • Papillomavirus vaccines
  • Squamous cell

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this